Dr Lal PathLabs vs Metropolis Healthcare: Which Stock Should You Track

August 6, 2026
Posted by: Ankit Jaiswal
Category: News

Dr Lal PathLabs MCap Rs 31,657 Cr, PE 57.94x, ROE 20.13%, D/E 0.08. Metropolis Healthcare MCap Rs 12,195 Cr, PE 63.80x, ROE 12.56%, D/E 0.15.

Dr Lal PathLabs vs Metropolis Healthcare is a comparison diagnostic lab investors look up when evaluating two leading Indian pathology chains. Dr Lal PathLabs is the largest diagnostic chain in North India, headquartered in Delhi, while Metropolis Healthcare is a Mumbai-headquartered diagnostic chain with strength in West and South India. Both operate hub-and-spoke laboratory networks.

This Dr Lal PathLabs vs Metropolis Healthcare article covers reach and market position, key products, latest declared results and stock valuation. The Dr Lal PathLabs vs Metropolis Healthcare data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Table of Contents

Dr Lal PathLabs vs Metropolis Healthcare: Reach and Market Position

On the Dr Lal PathLabs side of the Dr Lal PathLabs vs Metropolis Healthcare comparison, Dr Lal PathLabs operates over 800 labs and 10,000-plus collection centres primarily in North, East and Central India, serving routine and specialised pathology. Market capitalisation is Rs 31,657 Cr.

Click Here – Get Free Investment Predictions

On the Metropolis Healthcare side of the Dr Lal PathLabs vs Metropolis Healthcare comparison, Metropolis Healthcare operates over 150 labs and 4,000-plus collection points primarily in West and South India, with international presence in Africa and the Middle East. Market capitalisation is Rs 12,195 Cr.

Dr Lal PathLabs vs Metropolis Healthcare: Key Products and Business Mix

In the Dr Lal PathLabs vs Metropolis Healthcare product comparison, Dr Lal PathLabs offers: Dr Lal PathLabs offers routine blood tests, specialised tests, genetics and wellness packages. P/E is 57.94x, ROE 20.13 percent, near-zero debt at 0.08. Dividend yield is 1.09 percent.

For Metropolis Healthcare in this Dr Lal PathLabs vs Metropolis Healthcare breakdown: Metropolis Healthcare offers routine and specialised pathology, wellness packages, and molecular and genomic testing. P/E is 63.80x, ROE 12.56 percent, debt to equity 0.15.

Dr Lal PathLabs vs Metropolis Healthcare: Latest Results

The Dr Lal PathLabs vs Metropolis Healthcare results for Dr Lal PathLabs: Dr Lal PathLabs has a market cap of Rs 31,657 Cr and P/E of 57.94x. ROE is 20.13 percent. Dr Lal is 2.6 times larger than Metropolis by market cap.

The Dr Lal PathLabs vs Metropolis Healthcare results for Metropolis Healthcare: Metropolis Healthcare has a market cap of Rs 12,195 Cr and P/E of 63.80x. ROE is 12.56 percent.

Compare Dr Lal PathLabs and Metropolis Healthcare Fundamentals on the Univest Screener

Dr Lal PathLabs vs Metropolis Healthcare: Stock and Valuation

The Dr Lal PathLabs vs Metropolis Healthcare stock comparison uses the latest available market data from Groww. Investors tracking Dr Lal PathLabs vs Metropolis Healthcare should verify current prices on NSE or BSE before trading.

Dr Lal PathLabs trades at a market cap of Rs 31,657 Cr and P/E of 57.94x with ROE of 20.13 percent. Metropolis Healthcare trades at Rs 12,195 Cr market cap and P/E of 63.80x — slightly more expensive — with a lower ROE of 12.56 percent. Dr Lal delivers a much higher return on capital.

Dr Lal PathLabs vs Metropolis Healthcare: Quick Comparison Table

The Dr Lal PathLabs vs Metropolis Healthcare comparison table below summarises the key metrics covered in this article side by side.

Parameter	Dr Lal PathLabs	Metropolis Healthcare
Sector	Diagnostic chain: pathology and wellness	Diagnostic chain: pathology and specialised testing
Market Cap	Rs 31,657 Cr	Rs 12,195 Cr
P/E Ratio	57.94x	63.80x
ROE	20.13%	12.56%
Debt to Equity	0.08	0.15
Dividend Yield	1.09%	0.85%
Geographic strength	North, East and Central India	West and South India, international
Labs network	800-plus labs, 10,000-plus collection centres	150-plus labs, 4,000-plus collection points

Conclusion

The Dr Lal PathLabs vs Metropolis Healthcare comparison above covers the key data points on reach, products, results and valuation. Dr Lal PathLabs vs Metropolis Healthcare are two leading Indian diagnostic chains. Dr Lal is larger, has a higher ROE and trades at a slightly cheaper P/E with a dividend. Metropolis has a deeper West and South India presence. Investors should review test volume growth, average revenue per test and network expansion and consult a SEBI-registered advisor before investing.

Download the Univest iOS App or Univest Android App to track Dr Lal PathLabs and Metropolis Healthcare live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is the main difference between Dr Lal PathLabs and Metropolis Healthcare?

Ans. Dr Lal PathLabs is India’s largest diagnostic chain in North India. Metropolis Healthcare has strength in West and South India and international diagnostic labs in Africa and the Middle East.

Which company has the higher ROE?

Ans. Dr Lal PathLabs has an ROE of 20.13 percent, significantly higher than Metropolis Healthcare at 12.56 percent.

Which stock trades at a lower P/E?

Ans. Dr Lal PathLabs trades at 57.94x trailing earnings, slightly lower than Metropolis at 63.80x.

Does Metropolis operate outside India?

Ans. Yes. Metropolis Healthcare has diagnostic labs in Africa (Kenya, Nigeria) and the Middle East.

What risks apply to diagnostic chains?

Ans. Both companies face risk from commoditisation of routine tests, competition from single-owner pathology labs, online testing aggregators and any health insurance pricing changes.

What are the growth drivers for diagnostic labs?

Ans. Both benefit from increasing health awareness, preventive health checkup culture, chronic disease management testing and corporate wellness programme demand.

Should I invest in Dr Lal PathLabs or Metropolis?

Ans. Dr Lal has higher ROE and a dividend at a slightly lower P/E. Metropolis has geographic diversification. Consult a SEBI-registered advisor before investing.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.